Psychemedics Corp.  

(Public, NASDAQ:PMD)   Watch this stock  
Find more results for PMD
11.38
+0.12 (1.07%)
Real-time:   1:39PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.10 - 11.38
52 week 9.46 - 12.49
Open 11.24
Vol / Avg. 4,470.00/9,369.00
Mkt cap 60.00M
P/E 20.18
Div/yield 0.15/5.27
EPS 0.56
Shares 5.27M
Beta 0.93
Inst. own 50%
Aug 5, 2013
Q2 2013 Psychemedics Corporation Earnings Release Add to calendar
May 23, 2013
Psychemedics Corporation Annual Shareholder Meeting - 2:00PM EDT - Add to calendar
May 7, 2013
Q1 2013 Psychemedics Corporation Earnings Release
Feb 25, 2013
Q4 2012 Psychemedics Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 4.82% 11.81%
Operating margin 8.20% 19.57%
EBITD margin - 21.89%
Return on average assets 7.68% 21.34%
Return on average equity 9.57% 26.77%
Employees 132 -
Carbon Disclosure Rating - -

Address

Suite 200, 125 Nagog Park
ACTON, MA 01720
United States - Map
+1-978-2068220 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Psychemedics Corporation provides testing services for the detection of abused substances through the analysis of hair samples. The Company�s testing methods utilize a technology to enzymatically dissolve hair samples and then perform radioimmunoyassays on the hair sampled, with confirmation testing by mass spectrometry. Its primary application of its technology is as a testing service that analyzes hair samples for the presence of certain drugs of abuse. Its tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time providing superior detection compared to other types of drug testing. It provides commercial testing and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phencyclidine (PCP), methamphetamine and opiates. Testing services are performed at its laboratory in Culver City, California.

Officers and directors

Raymond C. Kubacki Jr. Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Neil L. Lerner Vice President - Finance, Treasurer
Age: 45
Bio & Compensation  - Reuters
Michael I. Schaffer Ph.D. Vice President - Laboratory Operations
Age: 68
Bio & Compensation  - Reuters
Sarah Ashby Vice President, General Counsel
Bio & Compensation  - Reuters
James V. Dyke Corporate Vice President - Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Harry F. Connick Independent Director
Age: 87
Bio & Compensation  - Reuters
Walter S. Tomenson Independent Director
Age: 66
Bio & Compensation  - Reuters
Fred J. Weinert Independent Director
Age: 65
Bio & Compensation  - Reuters